Metoprolol Population Pharmacokinetics in Older Chinese Patients With CKM Syndrome: Joint Effects of rs1065852 and CKM2S2-BAG Score on Clearance [0.03%]
洛尔在老年慢性肾病患者中的人群药代动力学：基因型rs1065852和CKD2S2-BAG评分对清除率的联合影响
Haodi Chai,Jie En Valerie Sia,Dingyuan Hu et al.
Haodi Chai et al.
Older adults are vulnerable to adverse drug reactions due to multimorbidity, frailty and polypharmacy. In those with cardiovascular-kidney-metabolic (CKM) syndrome, CKM-related multi-organ burden may further alter drug disposition and eleva...
Evaluation of a Novel Peptide-Based ELISA for the Serological Diagnosis of Trypanosoma cruzi Infection [0.03%]
一种新型肽基ELISA方法在查加斯病血清学诊断中的评价研究
Alicia Majeau,Julio Vladimir Cruz-Chan,Etienne Waleckx et al.
Alicia Majeau et al.
Chagas disease is a neglected tropical disease endemic in most of the Americas, caused by Trypanosoma cruzi. New serological tests with improved performance are urgently needed for accurate diagnosis of T. cruzi infections. We evaluated her...
Anti-PEG Antibodies From mRNA COVID-19 Vaccines Affect In Vitro Measurements of Pegylated Drug Levels [0.03%]
由mRNA新冠疫苗诱导的抗PEG抗体影响聚乙二醇化药物水平的体外测定
Elizaveta A Svyatova,Zhuoming Liu,Robyn E Becker et al.
Elizaveta A Svyatova et al.
The recent adoption of mRNA-based technology for vaccine development has led to widespread exposure to new vaccine components, such as polyethylene glycol (PEG), against which antibodies may be made. This study assesses the presence of anti...
Liquid Chromatography-Tandem Mass Spectrometry Quantification of Diet-Derived CYP2D6 Biomarkers for Clinical Phenotyping in Japanese Subjects [0.03%]
液相色谱-串联质谱法定量饮食来源的CYP2D6生物标志物以进行临床表型分型：日本人群中的应用
Masaki Kumondai,Nagomi Hayashi,Yotaro Matsumoto et al.
Masaki Kumondai et al.
The enzymatic activity of cytochrome P450 2D6 (CYP2D6) exhibits substantial interindividual variation, which influences drug efficacy and the risk of adverse drug reactions to various therapeutics. While current protocols for CYP2D6 genotyp...
Exploring Risks of Adverse Drug Events From Single Drug to Three-Drug Combination [0.03%]
从单一药物到三种药物联合使用探索不良用药事件的风险
Yi Shi,Anna Sun,Chien-Wei Chiang et al.
Yi Shi et al.
Use of three-drug combinations is common and could increase the risk of adverse drug events (ADEs). Signals of ADEs from three-drug combinations could be identified from real-world data, and the risks of ADEs from single drug exposure to th...
Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Olamkicept up to 2400 mg in Healthy Men: Phase I, Randomized, Placebo-Controlled, and Double-Blind Trial [0.03%]
奥拉克西普在健康男性中单次和多次给药至2400毫克的安全性与药代动力学：I期随机、双盲、安慰剂对照试验
Stanislav Ignatenko,Alla Radicke,Katharina Bruzelius et al.
Stanislav Ignatenko et al.
Olamkicept is a first-in-class fully human fusion protein that selectively inhibits trans interleukin (IL)-6 signaling. Previous phase I clinical trials demonstrated that single doses up to 750 mg and multiple doses up to 600 mg were safe a...
Clinical Trial
Clinical and translational science. 2026 Aug;19(8):e70674. DOI:10.1111/cts.70674 2026
Reimagining Bioequivalence for the Era of Complex Drug Products: A Quantitative Framework for Generic Drug Development [0.03%]
复杂药物产品时代的生物等效性再思考：通用药物开发的定量框架
Allison Dunn,Sooyoung Lee,Jogarao V S Gobburu
Allison Dunn
Ligelizumab Immunogenicity and Impact on Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety in Patients With Chronic Spontaneous Urticaria [0.03%]
ligelizumab的免疫原性及其对慢性自发性荨麻疹患者药代动力学、药效学、疗效和安全性的影响
Yan Ji,Claudio Calonder,Tiina Kirsiläe et al.
Yan Ji et al.
Ligelizumab is a highly potent, humanized IgG1 anti-IgE monoclonal antibody that was developed to treat chronic spontaneous urticaria (CSU). The immunogenicity of ligelizumab and its clinical impact were investigated in CSU patients followi...
Clinical Trial
Clinical and translational science. 2026 Jul;19(7):e70661. DOI:10.1111/cts.70661 2026
Reply to: "Hypoxia-Induced Lineage Plasticity in Neuroblastoma: Advancing Signature Interpretation and Clinical Translation" [0.03%]
关于“神经母细胞瘤中的缺氧诱导的谱系可塑性：推进标志解析和临床转化”的回复
Gepoliano S Chaves,Mohansrinivas Chennakesavalu,Kelley Moore et al.
Gepoliano S Chaves et al.
Population Pharmacokinetics of Intravenous Infusion of Hydromorphone in Critically Ill Patients Supported by Extracorporeal Membrane Oxygenation [0.03%]
体外膜氧合支持下的重症患者静脉滴注羟考酮的群体药代动力学分析
Xuehui Gao,Lu Yao,Fang Zeng et al.
Xuehui Gao et al.
The pharmacological properties of hydromorphone, including lower lipophilicity and reduced protein binding, suggest that it may have less sequestration in the circuit with more predictable pharmacokinetics (PK) during extracorporeal membran...